Nope, that’s not another delivery warehouse at the corner of Sievers Duecy Blvd. and Glenwood Avenue in Everett, Washington. It’s a 270,000-square-foot-facility dedicated to cancer research and development of medicines. Initial plans were filed with the City of Everett last June and construction has recently started. Here’s more about the project in a press release out today from Seagen.
Construction began earlier this year with the facility expected to open in 2024.
An artist’s rendering of the facility provided by Seagen.
The 270,000-square-foot facility will be built north of the company’s U.S. headquarters in Bothell, Washington.
Seagen expects to have the facility operational in 2024 and ultimately employ up to 200 highly skilled workers to produce medicines for clinical trials and the commercial market.
“In cancer research and development, Seagen must continue to be agile and flexible, especially in manufacturing, to advance our promising pipeline of medicines for people living with cancer and bring these medicines to patients as fast as possible,” said Clay Siegall, Ph.D., President and Chief Executive Officer, Seagen. “This new biomanufacturing facility is another way we are growing and expanding operations while also positioning ourselves to attract top-flight talent to drive our business priorities.”
The new biomanufacturing facility is a “greenfield” project, constructed from the ground up into a modern production facility to make advanced medicines. Seagen plans to make antibody-based medicines (also called biologics) in the new fully integrated plant for the commercial market and for use in clinical sites around the world.
The new facility will add to Seagen’s existing manufacturing site in the Bothell area. This project will create up to 150 new jobs during the initial construction of the shell and core of the building.
Seagen has four marketed therapies used in the treatment of Hodgkin lymphoma and urothelial (bladder), breast and cervical cancers. In research and development, Seagen is advancing more than 17 programs, including approved products and a deep and diverse early- and late-stage pipeline across a range of solid tumors and hematologic malignancies.
As a global biotech company, Seagen employs more than 2,800 people worldwide including more than 1,600 people in the Pacific Northwest.
Everett Mayor Cassie Franklin had this to say via email to MyEverettNews.com regarding Seagen selecting Everett:
“Seagen is the leading biotech company in our region and this new facility will complement Everett’s world-class advanced manufacturing workforce. I am thrilled they chose Everett for their expansion and look forward to welcoming Seagen and its family of employees to our city.”
April 20, 2022
Everett Economy